Epstein-Barr Virus BBRF2 Is Required for Maximum Infectivity.
BAC
BBRF2
CRISPR/Cas9
EBV
lytic cycle
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
16 Dec 2019
16 Dec 2019
Historique:
received:
13
11
2019
revised:
11
12
2019
accepted:
14
12
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
epublish
Résumé
Epstein-Barr virus (EBV) is a member of the gammaherpesvirinae, which causes infectious mononucleosis and several types of cancer. BBRF2 is an uncharacterized gene of EBV and is expressed during the lytic phase. To evaluate its function, BBRF2-knockout EBV was prepared using bacterial artificial chromosome (BAC) technology and the CRISPR/Cas9 system. Although viral gene expression, DNA synthesis, and progeny secretion were not affected, the infectivity of progeny viruses was significantly reduced by the disruption of BBRF2. When expressed alone, BBRF2 protein localized to the nucleus and cytoplasm, while the coexpression of an interacting partner, BSRF1, resulted in its relocalization to the cytoplasm. Interestingly, the coexpression of BBRF2 protected BSRF1 from proteasome/ubiquitin-dependent degradation. Therefore, BBRF2, together with BSRF1, augments viral infectivity.
Identifiants
pubmed: 31888254
pii: microorganisms7120705
doi: 10.3390/microorganisms7120705
pmc: PMC6955869
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 19K07580, 17H04081
Organisme : Japan Agency for Medical Research and Development
ID : JP17fm0208016, JP16ek0109098
Organisme : Takeda Science Foundation
ID : na
Organisme : Hori Sciences and Arts Foundation
ID : na
Références
Cell Microbiol. 2013 Feb;15(2):248-69
pubmed: 23186167
J Virol. 2003 May;77(9):5339-51
pubmed: 12692236
mSphere. 2018 Apr 25;3(2):
pubmed: 29695622
Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16286-91
pubmed: 15534216
J Virol. 2017 Nov 14;91(23):
pubmed: 28904200
Microbiol Immunol. 2014 Jun;58(6):307-17
pubmed: 24786491
J Virol. 2014 Aug;88(16):9086-99
pubmed: 24899189
J Gen Virol. 2009 Oct;90(Pt 10):2331-41
pubmed: 19553389
J Virol. 2014 Apr;88(8):4058-68
pubmed: 24453372
Virology. 2009 Jun 20;389(1-2):75-81
pubmed: 19427010
Adv Exp Med Biol. 2018;1045:395-412
pubmed: 29896677
J Virol. 2014 Jun;88(11):6411-22
pubmed: 24672041
J Virol. 2015 Mar;89(6):3112-22
pubmed: 25552711
J Virol. 2017 Jan 3;91(2):
pubmed: 27852850
Pediatr Blood Cancer. 2013 Dec;60(12):2068-72
pubmed: 24000236
J Virol. 2005 Sep;79(17):11291-9
pubmed: 16103181
J Virol. 2005 Mar;79(6):3831-40
pubmed: 15731276
J Virol. 2012 Sep;86(18):9647-55
pubmed: 22740416
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50
pubmed: 9653172
J Virol. 2013 Apr;87(7):4060-70
pubmed: 23365429
Viruses. 2019 Aug 02;11(8):null
pubmed: 31382485
PLoS Pathog. 2009 Sep;5(9):e1000570
pubmed: 19730696
J Biol Chem. 2006 Jul 28;281(30):20788-800
pubmed: 16720573
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Front Microbiol. 2017 Jan 31;8:125
pubmed: 28197146
Virology. 2014 Apr;454-455:67-77
pubmed: 24725933
Curr Top Microbiol Immunol. 2015;390(Pt 1):71-102
pubmed: 26424644
J Virol. 2014 Jan;88(1):110-9
pubmed: 24131716
J Virol. 2005 Mar;79(6):3409-18
pubmed: 15731235
J Virol. 2013 Feb;87(4):2120-7
pubmed: 23221557
Viruses. 2019 Mar 21;11(3):
pubmed: 30901892
J Virol. 2011 May;85(10):5125-35
pubmed: 21345947
J Virol. 1996 Feb;70(2):1091-9
pubmed: 8551568
J Virol. 2003 Mar;77(5):3204-16
pubmed: 12584344
J Virol. 2018 Aug 29;92(18):
pubmed: 29976672
Virology. 2015 Sep;483:44-53
pubmed: 25965794
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3805-10
pubmed: 15738413
Virology. 2019 May;531:114-125
pubmed: 30856483
Virology. 2015 Oct;484:33-40
pubmed: 26057150
J Virol. 2006 Jun;80(11):5125-34
pubmed: 16698993